BusinessPhoto: Business StandardBiocon Clears Patent Path for Breast Cancer Biosimilar Pebrilzo
Biocon has reached a global patent settlement with Genentech, allowing it to launch its breast cancer biosimilar Pebrilzo (pertuzumab) in major markets. The biosimilar can enter the EU and UK from Q1 2027 and the US from Q3 2028, pending approvals. This resolves patent disputes and opens significant commercial opportunities against Roche’s Perjeta, which had nearly 3 billion Swiss francs in sales in 2025.
Business Standard·


